Recently, it was shown that genetic ACLY deficiency or ACLY inhibition leads to increased immunogenicity and, consequently, inhibits the development/progression of hepatocellular carcinoma,16 supporting the notion that Tgr5 modulates cellfunction via metabolic-epigenetic pathways. The gene discussed is GPBAR1; the disease is hepatocellular carcinoma.